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Hiroshi Iwamoto1,2*, Jing Gao1, Ville Pulkkinen1, Tuula Toljamo3, Pentti Nieminen4 and Witold Mazur1Abstract
Background: The receptor for advanced glycation end-products (RAGE) is highly expressed in the lung, where it is
believed to have a homeostatic role. Reduced plasma levels of soluble RAGE (sRAGE) have been reported in patients
with chronic obstructive pulmonary disease (COPD). The aim of the present study was to evaluate the association
of plasma sRAGE levels with a longitudinal decline of lung function. We have also measured plasma levels of high
mobility group box 1 (HMGB1), a RAGE ligand which has been associated with chronic inflammatory diseases
including COPD.
Methods: Baseline plasma concentrations of sRAGE and HMGB1 were measured in non-smokers (n = 32), smokers
without COPD (n = 212), and smokers with COPD (n = 51), and the associations of the plasma sRAGE and HMGB1
levels with longitudinal declines of lung function during a 4-year follow-up period were analysed.
Results: The plasma levels of sRAGE were significantly lower in smokers without COPD and in smokers with COPD,
as compared to those of non-smokers. Plasma sRAGE levels positively correlated with FVC and FEV1 and inversely
correlated with BMI and pack-years. Lower sRAGE levels were associated with greater declines of FEV1/FVC over
4 years in all participants. Moreover, multivariate regression analysis indicated that the baseline plasma sRAGE
concentration was an independent predictor of FEV1/FVC decline in all groups. A subgroup analysis showed that
decreased sRAGE levels are significantly associated with a more rapid decline of FEV1/FVC in smokers with COPD.
There was no significant correlation between plasma HMGB1 levels and longitudinal decline of lung function.
Conclusions: Lower plasma concentrations of sRAGE were associated with greater progression of airflow limitations
over time, especially in smokers with COPD, suggesting that RAGE might have a protective role in the lung.Background
The receptor for advanced glycation end-products (RAGE)
is a cell-surface receptor belonging to the immunoglobulin
superfamily [1]. RAGE is a pattern-recognition receptor
that binds multiple ligands, and in most normal tissues it
is typically expressed at low levels or is undetectable. How-
ever, in the lung, RAGE is highly expressed even under
normal physiological conditions, and it is believed to have
a homeostatic function [2]. We have previously reported
that the expression of RAGE is significantly decreased in
the COPD lung, especially in severe disease [3]. Recent
cross-sectional studies, including one conducted by our* Correspondence: iwamotohiroshig@gmail.com
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unless otherwise stated.group, have consistently shown that circulatory levels of
the soluble isoform of RAGE (sRAGE) are reduced in
COPD patients [4-8]. Additionally, reduced circulatory
sRAGE levels are associated with more severe airflow limi-
tation [8,9], reduced diffusion capacity, and emphysema
[6,8] in COPD patients.
High-mobility group box 1 (HMGB1) is a chromatin
protein that is released from necrotic cells or activated
immune cells [10]. Extracellular HMGB1 is capable of
interacting with RAGE or Toll-like receptor and activat-
ing a pro-inflammatory cascade [11]. It has recently been
shown that HMGB1 is up-regulated in COPD lung tissue
and co-localised with RAGE [12]. Furthermore, circula-
tory HMGB1 levels are elevated in patients with COPD,
especially in those with more severe airflow limitation or
in cases complicated by comorbid lung cancer [13-15].
The findings of these recent cross-sectional studies
have supported an association of RAGE and its ligandal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Iwamoto et al. BMC Pulmonary Medicine 2014, 14:68 Page 2 of 7
http://www.biomedcentral.com/1471-2466/14/68HMGB1 with the progression of COPD. However, little
is known about the correlation of these molecules and
pulmonary function decline over time. The aim of the
present study was to perform a longitudinal cohort study
to evaluate plasma levels of sRAGE and HMGB1 in
non-smokers, smokers without COPD, and smokers with
COPD, and to estimate the predictive value of sRAGE
and HMGB1 levels for decline of lung function over
time. We examined the association between longitudinal
changes of spirometric variables during 4 years and base-
line plasma levels of sRAGE and HMGB1 along with
demographic variables at the baseline visit including age,
BMI, smoking status, and spirometric measurements.
Methods
Participants
The participants in the present study were part of a lon-
gitudinal cohort survey of smokers and non-smokers
conducted in northern Finland. The details of the pro-
ject and the inclusion and exclusion criteria have been
published elsewhere [16,17]. In brief, the exclusion cri-
teria were presence of lung disease or other disease; use
of regular medication; risk factors for lung disease such
as allergies, infections, and exposures; history of asthma
or any previous lung infection including pneumonia or
bronchiectasis; malignancy; and viral infection during
the previous 2 months [16]. Based on a detailed self-
reported questionnaire, all participants considered them-
selves healthy.
All of the smokers in the study had a cigarette smok-
ing history of ≥10 years. The diagnosis of COPD was de-
fined according to the Global Strategy for the diagnosis,
management, and prevention of COPD (GOLD) criteria,
i.e. FEV1/FVC <70% and bronchodilator effect <12% re-
lated to long-term smoking [18,19]. All COPD diagnoses
in the study cohort were confirmed during the study
period; none of the participants had any previously pre-
scribed medications for COPD or other diseases.
The non-smoking study participants (non-smokers)
were enrolled if they were >40 years of age, were healthy
and not taking any medications, and had normal lung
function according to the GOLD criteria for obstruction
described above.
From 2007 to 2008, we collected baseline spirometric
measurements and plasma samples from 345 partici-
pants. Follow-up spirometric measurements were taken
4 years later, from 2011 to 2012, and there were 295 partic-
ipants with a baseline blood sample as well as baseline spir-
ometry and follow-up spirometry. Post-bronchodilation
values were used for the assessment of longitudinal change
of lung function. The study was approved by the Ethics
Committee of Lapland Central Hospital (4th June 2003
and 31st October 2006), and all participants provided writ-
ten informed consent.Plasma samples
Peripheral whole venous blood was collected in EDTA
tubes. Plasma was prepared by centrifugation for 10 to
15 min at 1500 rpm and stored at −80°C until analysis.
Measurement of plasma sRAGE and HMGB1 concentrations
Plasma levels of sRAGE and HMGB1 were measured by
commercially available ELISA kits (R & D Systems,
Minneapolis, MN, USA and Uscn Life Science Inc, Wuhan,
China, respectively) according to the manufacturer in-
structions. The detection limits for sRAGE and HMGB1
were 78 pg/mL and 0.238 ng/mL, respectively.
Statistical analysis
The results are expressed as mean ± standard deviation
(SD) if not stated otherwise. The analyses of variance
(ANOVA) and t-test for independent groups were used
to check for statistical significance in differences in par-
ticipant characteristics and plasma levels of sRAGE and
HMGB1 among the study groups. Spearman’s rank cor-
relation was used to evaluate the associations of plasma
sRAGE and HMGB1 concentrations with other vari-
ables. To estimate the independent effects of explanatory
variables for the changes in lung functions during the
4 years, multivariate regression analysis was performed
for each dependent lung function. The data were analysed
with a statistical software package (SPSS for Windows,
version 21.0; SPSS Inc; Chicago, IL).
Results
Participant characteristics
The baseline demographic and clinical characteristics of
participants in each of the study groups (non-smokers,
smokers without COPD, and smokers with COPD) are
shown in Table 1. The smokers without COPD were sig-
nificantly younger than the non-smokers and the
smokers with COPD. There were no significant differ-
ences in BMI among the three groups. FEV1 was signifi-
cantly lower in smokers with COPD than in the other
two groups. FEV1/FVC was also significantly lower in
smokers without COPD than in non-smokers (p = 0.014)
and further reduced in smokers with COPD in compari-
son with that in smokers without COPD (p < 0.001).
Baseline plasma sRAGE and HMGB1 concentrations
The baseline plasma levels of sRAGE (mean ± SD) were
significantly lower in smokers without COPD and
smokers with COPD (973.4 ± 426.5 pg/mL and 969.1 ±
406.0 pg/mL, respectively) than in non-smokers (1201.1 ±
483.6 pg/mL) (Figure 1). There was no significant differ-
ence in mean plasma HMGB1 concentrations among the
three groups (non-smokers, 1.8 ± 1.1 ng/mL; smokers
without COPD, 1.9 ± 1.1 ng/mL; smokers with COPD, 1.8 ±
1.7 ng/mL; figure not shown). There was no significant
Table 1 Baseline characteristics of study participants
All Non-smokers Smokers without COPD Smokers with COPD
Subjects, n 295 32 212 51
M/F 161/134 10/22 109/103 42/9
Age years 53.7 ± 9.3 56.0 ± 9.1 52.1 ± 8.8 58.9 ± 9.0
BMI 27.0 ± 3.8 27.0 ± 3.9 26.9 ± 3.8 27.3 ± 3.9
Smoking status
Former smoker n (%) 56 (19%) 0 44 (21%) 12 (23%)
Current smoker n (%) 207 (70%) 0 168 (79%) 39 (77%)
Pack-years 26.8 ± 16.7 0 28.3 ± 14.1 37.6 ± 14.1
Symptom
Only Cough n (%) 17 (5.9%) 0 (0%) 13 (6.1%) 4 (7.8%)
Only Sputum n (%) 58 (20.1%) 6 (23.1%) 47 (22.2%) 5 (9.8%)
Both Cough and sputum n (%) 97 (33.6%) 2 (7.7%) 71 (33.5%) 24 (47.1%)
Pre-bronchodilator
FVC L 3.9 ± 0.9 3.7 ± 0.8 4.0 ± 0.9 3.9 ± 0.9
FVC % predicted 96.2 ± 12.5 102.6 ± 13.4 96.6 ± 11.5 90.9 ± 14.1
FEV1 L 3.0 ± 0.8 3.2 ± 0.7 3.2 ± 0.8 2.5 ± 0.7
FEV1 % predicted 90.8 ± 16.9 108.1 ± 13.5 94.6 ± 13.0 70.4 ± 15.5
FEV1/FVC % 76.8 ± 9.3 81.4 ± 5.3 79.5 ± 6.1 62.9 ± 9.4
Post-bronchodilator
FVC L 4.0 ± 1.0 3.7 ± 0.8 4.0 ± 1.0 4.1 ± 1.0
FVC % predicted 96.7 ± 12.6 105.0 ± 9.9 96.5 ± 12.4 95.2 ± 13.4
FEV1 L 3.1 ± 0.8 3.1 ± 0.6 3.3 ± 0.8 2.6 ± 0.7
FEV1 % predicted 93.3 ± 16.3 110.6 ± 13.6 96.8 ± 12.8 74.3 ± 14.8
FEV1/FVC % 78.7 ± 9.3 84.3 ± 5.3 81.6 ± 5.5 62.9 ± 7.7
Values are mean ± SD unless stated otherwise.
BMI, Body mass index; COPD, Chronic obstructive pulmonary disease; FEV1, Forced expiratory volume in 1 s; FVC, Forced vital capacity.
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any of the subjects or in any of the groups in the present
study (p > 0.05).
Correlation of sRAGE and lung function
Plasma sRAGE levels were inversely correlated with
BMI and pack-years and positively correlated with FVC
and FEV1 (Table 2). In a subgroup analysis, there were
weak but statistically significant correlations between
plasma sRAGE concentrations and BMI and FVC and
FEV1 only in smokers without COPD. There was a simi-
lar trend in smokers with COPD, but the p-value did not
reach statistical significance (p > 0.05). There was no sig-
nificant correlation between presence of chronic cough
and/or sputum at the baseline visit and the plasma levels
of sRAGE and HMGB1 in any of the subjects or among
any of the study groups (p > 0.05). There was no signifi-
cant association between plasma HMGB1 levels and
baseline cross-sectional parameters in any of the groups
(data not shown).Correlation between reduced sRAGE and progression of
airflow limitation
Longitudinal changes of FEV1 (mean±SEM) in non-
smokers, smokers without COPD, and smokers with COPD
during the 4-year study period were −243 ± 37 mL, −325 ±
18 mL, and −355 ± 41 mL, respectively. The lower plasma
sRAGE concentrations in all groups were significantly asso-
ciated with longitudinal decline of FEV1/FVC (ΔFEV1/
FVC) (Table 3, Figure 2), while there was no significant
association between longitudinal changes of lung function
and demographic characteristics or plasma HMGB1 levels
(data not shown). Additionally, a subgroup analysis showed
that a lower sRAGE concentration was significantly
associated with a greater decline of FEV1/FVC in smokers
with COPD (Table 3, Figure 2). For smokers with COPD,
a trend became evident between a decreased plasma
sRAGE level and a longitudinal decline in FEV1 (Table 3,
Additional file 1: Figure S1). There were 13 smokers with
COPD who had started an inhaled medication, i.e. a bron-




















Figure 1 Plasma levels of soluble receptor for advanced glycation
end-products (sRAGE). The boxes represent the 25th to 75th
percentiles; the solid lines within the boxes show the median values;
the whiskers are the 10th and 90th percentiles; and the points
represent outliers. *: p < 0.05 and **: p < 0.01 (between 2 groups, t-test).
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significant correlation between baseline sRAGE levels and
decline of FEV1/FVC (r = 0.362, p = 0.025). Finally, mul-
tiple stepwise regression analysis was performed in order
to investigate the association of FEV1/FVC decline with
sRAGE levels together with previously reported predictors
of lung function decline, including age, sex, BMI, current
smoking status, and baseline lung function [20-22]. In this
multivariate analysis, lower baseline sRAGE levels were anTable 2 Correlations between plasma sRAGE concentrations a
All Non-smokers
(n = 295) (n = 32)
r p-value r p-value
Age −0.053 0.362 0.106 0.563
BMI −0.139 0.017* 0.260 0.151
Pack-year −0.149 0.010* - -
FVC 0.130 0.026* 0.119 0.518
FVC % predicted 0.190 0.001** 0.042 0.829
FEV1 0.126 0.030* 0.116 0.526
FEV1 % predicted 0.136 0.020* 0.044 0.821
FEV1/FVC −0.029 0.620 0.070 0.245
*: p < 0.05; **: p < 0.01 (correlation with plasma sRAGE levels by Spearman’s rank co
BMI, Body mass index; COPD, Chronic obstructive pulmonary disease; FEV1, Forced eindependent predictor for a more precipitous decline of
FEV1/FVC even after adjusting for all other variables
(p = 0.019) (Table 4). Age (p < 0.001), baseline FEV1/FVC
(p = 0.013), and current smoking (p = 0.014) were also
independent predictors for ΔFEV1/FVC.
Discussion
In the present study, we evaluated plasma concentra-
tions of sRAGE and HMGB1 in non-smokers, smokers
without COPD, and smokers with COPD, and we subse-
quently examined the association between these two
markers using baseline demographic data and the longi-
tudinal decline of lung function during a 4-year follow-
up period. Baseline plasma sRAGE levels were signifi-
cantly lower in smokers with and without COPD than in
non-smokers. Moreover, plasma sRAGE concentrations
were significantly associated with longitudinal declines
of FEV1/FVC, and this association remained significant
even after controlling for demographics and baseline
lung function. In contrast, there was no significant dif-
ference in plasma HMGB1 levels among the three
groups, nor were there any significant associations
among plasma HMGB1 concentration, baseline lung
function, and decline in lung function during the follow-
up period in any group.
To the best of our knowledge, this is the first study to
demonstrate that reduced plasma sRAGE levels are asso-
ciated with progression of airflow limitation. Interest-
ingly, this association was apparent in smokers with
COPD, but we could not perform a subgroup multiple
regression analysis for the COPD group because of its
limited sample size. Previously, circulating sRAGE in pa-
tients with COPD has been associated with emphysema
severity, impaired diffusion capacity, and airway neutro-
philic inflammation [5-8], supporting a possible role of
RAGE in alveolar integrity and the anti-inflammatory
properties of sRAGE [23-25]. A recent longitudinalnd baseline demographics
Smokers without COPD Smokers with COPD
(n = 212) (n = 51)
r p-value r p-value
−0.110 0.109 −0.061 0.670
−0.162 0.018* −0.272 0.053
−0.072 0.295 −0.262 0.063
0.140 0.042* 0.131 0.360
0.189 0.006** 0.163 0.252
0.133 0.054 0.151 0.291
0.164 0.017* 0.176 0.217
−0.064 0.353 0.138 0.335
rrelation coefficient).
xpiratory volume in 1 s; FVC, Forced vital capacity.
Table 3 Correlations between plasma sRAGE concentrations and longitudinal changes in lung function
All Non-smokers Smokers without COPD Smokers with COPD
(n = 295) (n = 32) (n = 212) (n = 51)
r p-value r p-value r p-value r p-value
ΔFVC −0.043 0.466 −0.142 0.438 −0.033 0.637 −0.031 0.828
ΔFVC % predicted −0.047 0.432 −0.187 0.540 −0.033 0.632 −0.014 0.922
ΔFEV1 0.061 0.294 −0.115 0.529 0.008 0.907 0.240 0.090
ΔFEV1 % predicted 0.059 0.332 −0.215 0.481 0.029 0.680 0.269 0.056
ΔFEV1/FVC 0.149 0.010* 0.259 0.153 0.053 0.445 0.326 0.019*
*: p < 0.05; (correlation with plasma sRAGE levels, by Spearman’s rank correlation coefficient).
COPD, Chronic obstructive pulmonary disease; Δ: changes from baseline after 4 years; FEV1, Forced expiratory volume in 1 s; FVC, Forced vital capacity; sRAGE,
Soluble receptor for advanced glycation end-products.
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sRAGE levels and decline of lung density in CT scans in
patients with moderate to severe COPD, suggesting the
possible association between RAGE and disease progres-
sion [26]. The present study showed that lower plasma
sRAGE levels were predictive for progression of airflow
limitation, which further supports the theory that RAGE
might have a protective role against progression of
COPD. Further investigation is needed to clarify the
mechanism of this association.
In the present study, the differences in plasma sRAGE
concentrations between smokers with COPD and
smokers in whom post-bronchodilator spirometry re-
sults did not meet the COPD criteria were not signifi-
cant. It should be noted that most of the participants in
the COPD group had only mild to moderate airflow
limitation in the present study. Recent cross-sectional
studies have shown that plasma sRAGE levels areFigure 2 Relationship between plasma sRAGE levels at baseline and t
receptor for advanced glycation end-products.decreased especially in COPD patients who have severe
disease [4,8,9], and circulatory sRAGE levels were sig-
nificantly reduced in accordance with advanced GOLD
stage in the COPD patients of the ECLIPSE cohort [8].
On the other hand, Boschetto et al. did not find a signifi-
cant difference in plasma sRAGE levels between healthy
volunteers and COPD patients with mild to moderate
airflow limitation, which is in agreement with the find-
ings of the present study [14]. Therefore, although we
did not observe a significant difference in circulatory
levels of sRAGE between smokers with COPD and
smokers without COPD, our results could still indicate
that an sRAGE deficiency might be associated with more
advanced COPD. A future large-scale study will be war-
ranted to determine whether plasma sRAGE would be
useful as an early diagnostic marker for COPD. Further-
more, we believe that the assessment of emphysema by
CT scans or diffusion capacity should be furtherhe change of FEV1/FVC during a 4 year follow-up. sRAGE: soluble
Table 4 Multivariate stepwise analysis of all participants
with ΔFEV1/FVC as the dependent variables*
β t test p value
Age −0.258 −4.295 <0.001
Baseline FEV1/FVC −0.160 −2.494 0.013
Current smoking −0.140 −2.466 0.014
Plasma sRAGE 0.134 2.364 0.019
Δ: changes from baseline after 4 years; FEV1, Forced expiratory volume in 1 s;
FVC, Forced vital capacity; sRAGE, Soluble receptor for advanced glycation
end-products.
*(n = 295). The other independent variables included in the model were sex
and BMI.
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nificantly associated with sRAGE levels independently of
airflow limitation in patients with COPD [6-8].
We found no difference between plasma HMGB1
levels among non-smokers, smokers without COPD and
smokers with COPD, and there was no significant asso-
ciation between plasma HMGB1 levels and spirometric
measurements. These findings varied from those of the
recent reports that indicated plasma HMGB1 levels were
elevated in patients with COPD, especially in those with
severe airflow limitation [13]. Hou et al. found signifi-
cantly elevated plasma HMGB1 levels using ELISA in
COPD patients in comparison with normal controls
[13]. We used the same ELISA method in our study, and
the HMGB1 levels in the controls were comparable with
those in the previous study [13]. However, a striking dif-
ference is that Hou et al. included COPD patients with
severe airflow limitation (mean %FEV1, 34.99%), and the
HMGB1 levels of those COPD patients were higher than
those of the control group. Shang et al. measured serum
HMGB1 levels by western blot in patients with non-
small cell lung cancer and in patients with COPD [27].
In their study, the serum HMGB1 levels were higher in
COPD patients with more severe airflow limitation
(mean %FEV1, 49%) when compared with the results in
the present study, and they found that patients with lung
cancer had even higher levels of serum HMGB1. In an-
other recent study that has reported elevated plasma
HMGB1 levels in patients with mild to moderate COPD,
82% of the COPD patients had comorbid lung cancer
[15]. In fact, our study is the first to compare circulatory
HMGB1 levels between never-smokers, a control group
of smokers without COPD, and smokers with early stage
COPD and no comorbidities, and the inconsistencies of
the HMGB1 levels in the COPD patients in the present
study and those of the previous studies are probably re-
lated to the differences in the background characteristics
of the study participants.
There were several limitations in the present study.
First, the number of participants in the non-smoker andsmoker with COPD groups was relatively small. A larger
sample size for the COPD group would be necessary to
confirm the association between sRAGE and decline of
lung function in a subgroup analysis. Additionally, be-
cause there were only 9 female participants in the COPD
group, we could not analyse gender-related differences
in longitudinal decline of lung function in the COPD
group. Secondly, we did not perform high-resolution
computed tomography or diffusion capacity studies.
Thirdly, the follow-up period of 4 years was relatively
short, but this was due to the study design of a longitu-
dinal analysis among apparently healthy middle-aged to
elderly populations. On the other hand, this study had
significant strengths. None of the participants had any
other exposures and no participants in any of the
groups, including those chronic smokers who were diag-
nosed with COPD, had any comorbidities and were not
taking any medications at the time of enrolment [16].
Conclusion
In conclusion, we have demonstrated that decreased
plasma sRAGE levels are associated with the progression
of airflow limitation, especially in smokers with COPD.
This suggests that RAGE might have a protective role
against the progression of smoking-induced lung dam-
age, although further studies are warranted to confirm
the present observation and to clarify the relationships
between the RAGE/HMGB1 pathway and its role in the
pathophysiology of COPD.
Additional file
Additional file 1: Figure S1. Relationship between plasma sRAGE levels
at baseline and the change of FEV1 during a 4 year follow-up. sRAGE:
soluble receptor for advanced glycation end-products.
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